PMID- 37938535
OWN - NLM
STAT- MEDLINE
DCOM- 20231216
LR  - 20231216
IS  - 1179-1918 (Electronic)
IS  - 1173-2563 (Linking)
VI  - 43
IP  - 12
DP  - 2023 Dec
TI  - Glucagon-Like Peptide-1 Receptor Agonist and Risk of Diabetic Retinopathy in 
      Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of 
      Randomized Placebo-Controlled Trials.
PG  - 915-926
LID - 10.1007/s40261-023-01319-x [doi]
AB  - BACKGROUND: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) exhibit 
      glucose-lowering, weight-reducing, and blood pressure-lowering effects. 
      Nevertheless, a debate exists concerning the association between GLP-1RA 
      treatment and the risk of diabetic retinopathy (DR) in patients diagnosed with 
      type 2 diabetes mellitus (T2DM). OBJECTIVE: To ascertain the risk of DR in 
      patients with T2DM undergoing GLP-1RA treatment, we conducted a meta-analysis 
      utilizing data derived from randomized placebo-controlled studies (RCTs). 
      METHODS: A comprehensive literature search was conducted using PubMed, Cochrane 
      Library, Web of Science, and EMBASE. We focused on RCTs involving the use of 
      GLP-1RAs in patients with T2DM. Utilizing R software, we compared the risk of DR 
      among T2DM patients undergoing GLP-1RA treatment. The Cochrane risk of bias 
      method was employed to assess the research quality. RESULTS: The meta-analysis 
      incorporated data from 20 RCTs, encompassing a total of 24,832 T2DM patients. 
      Across all included trials, randomization to GLP-1 RA treatment did not 
      demonstrate an increased risk of DR (odds ratio = 1.17; 95% CI 0.98-1.39). 
      Furthermore, no significant heterogeneity or publication bias was detected in the 
      analysis. CONCLUSION: The results of this systematic review and meta-analysis 
      indicate that the administration of GLP-1 RA is not associated with an increased 
      risk of DR. PROSPERO REGISTRATION IDENTIFIER: CRD42023413199.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Jiao, Xiaojuan
AU  - Jiao X
AD  - Department of Endocrinology and Metabolism, The Second Affiliated Hospital of 
      Nanchang University, No. 1, Minde Road, Donghu District, Nanchang, 330006, China.
AD  - Branch of National Clinical Research Center for Metabolic Diseases, Nanchang, 
      330006, China.
AD  - Institute for the Study of Endocrinology and Metabolism in Jiangxi Province, 
      Nanchang, 330006, China.
FAU - Peng, Ping
AU  - Peng P
AD  - Department of Endocrinology and Metabolism, The Second Affiliated Hospital of 
      Nanchang University, No. 1, Minde Road, Donghu District, Nanchang, 330006, China.
AD  - Branch of National Clinical Research Center for Metabolic Diseases, Nanchang, 
      330006, China.
AD  - Institute for the Study of Endocrinology and Metabolism in Jiangxi Province, 
      Nanchang, 330006, China.
FAU - Zhang, Qin
AU  - Zhang Q
AD  - Department of Endocrinology and Metabolism, The Second Affiliated Hospital of 
      Nanchang University, No. 1, Minde Road, Donghu District, Nanchang, 330006, China.
AD  - Branch of National Clinical Research Center for Metabolic Diseases, Nanchang, 
      330006, China.
AD  - Institute for the Study of Endocrinology and Metabolism in Jiangxi Province, 
      Nanchang, 330006, China.
FAU - Shen, Yunfeng
AU  - Shen Y
AUID- ORCID: 0000-0003-3404-8400
AD  - Department of Endocrinology and Metabolism, The Second Affiliated Hospital of 
      Nanchang University, No. 1, Minde Road, Donghu District, Nanchang, 330006, China. 
      syf92@live.com.
AD  - Branch of National Clinical Research Center for Metabolic Diseases, Nanchang, 
      330006, China. syf92@live.com.
AD  - Institute for the Study of Endocrinology and Metabolism in Jiangxi Province, 
      Nanchang, 330006, China. syf92@live.com.
LA  - eng
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20231108
PL  - New Zealand
TA  - Clin Drug Investig
JT  - Clinical drug investigation
JID - 9504817
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Glucagon-Like Peptide-1 Receptor Agonists)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - *Diabetic Retinopathy/epidemiology
MH  - Glucagon-Like Peptide 1/metabolism
MH  - Glucagon-Like Peptide-1 Receptor/agonists
MH  - Glucagon-Like Peptide-1 Receptor Agonists
MH  - Hypoglycemic Agents/adverse effects
MH  - Randomized Controlled Trials as Topic
EDAT- 2023/11/08 12:42
MHDA- 2023/12/11 12:43
CRDT- 2023/11/08 11:30
PHST- 2023/10/25 00:00 [accepted]
PHST- 2023/12/11 12:43 [medline]
PHST- 2023/11/08 12:42 [pubmed]
PHST- 2023/11/08 11:30 [entrez]
AID - 10.1007/s40261-023-01319-x [pii]
AID - 10.1007/s40261-023-01319-x [doi]
PST - ppublish
SO  - Clin Drug Investig. 2023 Dec;43(12):915-926. doi: 10.1007/s40261-023-01319-x. 
      Epub 2023 Nov 8.